Increasing patient participation in oncology clinical trials.
Increasing patient participation in oncology clinical trials.
复制标题
作者：
及时招募合格的参与者对于临床试验的成功至关重要，而累积不足是肿瘤学和非肿瘤学试验提前终止的主要原因。在本文中，我们从医生、患者、医疗保健系统和一些试验相关的角度进一步阐述了患者参与肿瘤学试验的挑战。我们提出的策略包括使用数字医疗技术、真实的世界数据和真实的世界证据、分散的临床试验、务实的试验设计和支持性服务，以增加患者的参与。多方面的措施是必要的，以增加患者的参与，特别是对于那些谁是在癌症试验代表性不足。及时招募合格的受试者对于临床试验的成功至关重要，招募不足是肿瘤学和非肿瘤学试验提前终止的主要原因。在本文中，我们从医生、患者、医疗保健系统和一些试验相关的角度进一步阐述了患者参与肿瘤学试验的挑战，并提出了一些策略，如使用数字医疗技术、真实的世界数据和真实的世界证据、分散临床试验、务实的试验设计和支持服务，以增加患者的参与。
Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of both oncology and non‐oncology trials. In this paper we further elaborate on the challenges for patient participation in oncology trials from physician, patient, healthcare system, and some trial‐related perspectives. We present strategies such as use of digital healthcare technologies, real‐world data and real‐world evidence, decentralized clinical trials, pragmatic trial designs, and supportive services to increase patient participation. Multifaceted measures are necessary to increase patient participation, especially for those who are under‐represented in cancer trials. Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of both oncology and non‐oncology trials. In this paper we further elaborate on the challenges for patient participation in oncology trials from physician, patient, healthcare system, and some trial‐related perspectives and present strategies such as use of digital healthcare technologies, real‐world data and real‐world evidence, decentralized clinical trials, pragmatic trial designs, and supportive services to increase patient participation.
影响因子：
3.8
作者：
Carey M;Boyes AW;Smits R;Bryant J;Waller A;Olver I
通讯作者：
Olver I